HHS: COVID-19 monoclonal antibody no longer authorized for use in U.S.
The Food and Drug Administration does not currently authorize the monoclonal antibody bamlanivimab for emergency use to treat mild-to-moderate COVID-19 in the United States because it is not expected to neutralize the predominating BQ.1 and BQ.1.1. omicron subvariants, the Department of Health and Human Services announced yesterday. Eli Lilly and its distributors have paused commercial distribution of the treatment; and HHS’ Administration for Strategic Preparedness and Response has paused distribution under the Bebtelovimab Product Replacement Initiative. Health care providers should use other approved or authorized treatment options, HHS said.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…